Evidence map›Paper›PMID 39916962›Full record

ReviewFrontiers in immunology2024

Immunotherapy of osteosarcoma based on immune microenvironment modulation.

Heping Lian, Jiakui Zhang, Shuna Hou, Shuang Ma, Jiachen Yu, Wei Zhao, Duoyi Zhao, Zhiyu Zhang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. LncSNHGs: new targets in osteosarcoma.Cancer gene therapy · 2025
    Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Heping Lian *Department of Orthopedics, The Fourth Affiliated Hospital of China Medical University, Shenyang, China.
Jiakui Zhang *Department of Surgical Oncology, The Fourth Affiliated Hospital of China Medical University, Shenyang, China.
Shuna Hou *Department of General Surgery, The Fourth Affiliated Hospital of China Medical University, Shenyang, China.
Shuang MaNursing Department, The Fourth Affiliated Hospital of China Medical University, Shenyang, China.
Jiachen YuDepartment of Orthopedics, The Fourth Affiliated Hospital of China Medical University, Shenyang, China.
Wei ZhaoDepartment of Orthopedics, The Fourth Affiliated Hospital of China Medical University, Shenyang, China.
Duoyi ZhaoDepartment of Orthopedics, The Fourth Affiliated Hospital of China Medical University, Shenyang, China.
Zhiyu ZhangDepartment of Orthopedics, The Fourth Affiliated Hospital of China Medical University, Shenyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteosarcoma is a highly malignant tumor with unsatisfactory therapeutic outcomes achieved by chemotherapy, radiotherapy, and surgery. As an emerging oncological treatment, immunotherapy has shown potential in the clinical management of many tumors but has a poor response rate in osteosarcoma. The immunosuppressive microenvironment in osteosarcoma is the main reason for the ineffectiveness of immunotherapy, in which the low immune response rate of immune effector cells and the high activation of immunosuppressive cells contribute to this outcome. Therefore, modulating the function of the immune microenvironment in osteosarcoma is expected to remodel the immunosuppressive microenvironment of osteosarcoma and enhance the efficacy of immunotherapy. This article reviews the role of immune cells in the progression of osteosarcoma, describes the corresponding regulatory tools for the characteristics of different cells to enhance the efficacy of osteosarcoma immunotherapy, and concludes the prospects and future challenges of osteosarcoma immunotherapy.

Indexed as

Bone NeoplasmsImmunotherapyOsteosarcomaTumor MicroenvironmentAnimalsHumansbiomaterialsimmune microenvironmentimmunotherapyosteosarcomatargeted therapy

Identifiers

PMID39916962
PMCPMC11799554

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.